Guangdong Jiaying Pharmaceutical Co Ltd Tangible Net Worth Ratio
Guangdong Jiaying Pharmaceutical Co Ltd tangible net worth ratio. Guangdong Jiaying Pharmaceutical Co Ltd (002198) has a Tangible Net Worth Ratio of 89.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥78.65 Million) from net assets (CN¥730.39 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check Guangdong Jiaying Pharmaceutical Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Guangdong Jiaying Pharmaceutical Co Ltd (2004–2025)
Tangible net worth ratio of Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2025. This chart shows how Guangdong Jiaying Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 22 annual periods from 2004 to 2025. As of March 2026, the ratio stands at 89.2%, reflecting net assets of CN¥730.39 Million with intangible assets of CN¥78.65 Million CNY. See working capital position of Guangdong Jiaying Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Guangdong Jiaying Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2004–2025)
Guangdong Jiaying Pharmaceutical Co Ltd tangible net worth ratio by year from 2004 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2025, covering 22 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 002198 market cap overview.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 89.4% | CN¥717.93 Million | CN¥76.11 Million | CN¥849.23 Million | ▼ -4.5 pp |
| 2024 | 93.9% | CN¥758.22 Million | CN¥45.89 Million | CN¥838.82 Million | ▲ +0.1 pp |
| 2023 | 93.8% | CN¥762.98 Million | CN¥47.21 Million | CN¥847.56 Million | ▲ +1.0 pp |
| 2022 | 92.8% | CN¥728.42 Million | CN¥52.37 Million | CN¥846.65 Million | ▲ +1.3 pp |
| 2021 | 91.5% | CN¥684.48 Million | CN¥58.29 Million | CN¥807.34 Million | ▲ +0.9 pp |
| 2020 | 90.6% | CN¥683.01 Million | CN¥64.16 Million | CN¥808.44 Million | ▲ +1.1 pp |
| 2019 | 89.5% | CN¥663.17 Million | CN¥69.46 Million | CN¥855.94 Million | ▼ -0.9 pp |
| 2018 | 90.4% | CN¥785.35 Million | CN¥75.33 Million | CN¥889.56 Million | ▲ +1.2 pp |
| 2017 | 89.2% | CN¥749.81 Million | CN¥81.22 Million | CN¥876.61 Million | ▼ -2.0 pp |
| 2016 | 91.2% | CN¥984.87 Million | CN¥87.10 Million | CN¥1.10 Billion | ▲ +1.2 pp |
| 2015 | 90.0% | CN¥929.70 Million | CN¥92.98 Million | CN¥1.05 Billion | ▲ +1.3 pp |
| 2014 | 88.7% | CN¥863.35 Million | CN¥97.37 Million | CN¥1.04 Billion | ▼ -2.0 pp |
| 2013 | 90.7% | CN¥809.66 Million | CN¥75.32 Million | CN¥919.00 Million | ▼ -8.0 pp |
| 2012 | 98.7% | CN¥278.08 Million | CN¥3.55 Million | CN¥314.25 Million | ▲ +0.3 pp |
| 2011 | 98.5% | CN¥270.51 Million | CN¥4.17 Million | CN¥306.55 Million | ▲ +0.3 pp |
| 2010 | 98.1% | CN¥258.47 Million | CN¥4.79 Million | CN¥300.87 Million | ▲ +0.4 pp |
| 2009 | 97.8% | CN¥241.42 Million | CN¥5.40 Million | CN¥253.33 Million | ▼ -0.3 pp |
| 2008 | 98.1% | CN¥226.35 Million | CN¥4.41 Million | CN¥235.24 Million | ▲ +0.5 pp |
| 2007 | 97.6% | CN¥212.62 Million | CN¥5.11 Million | CN¥245.48 Million | ▲ +4.6 pp |
| 2006 | 93.0% | CN¥82.63 Million | CN¥5.78 Million | CN¥120.05 Million | ▲ +1.6 pp |
| 2005 | 91.4% | CN¥64.39 Million | CN¥5.55 Million | CN¥91.23 Million | ▲ +3.9 pp |
| 2004 | 87.5% | CN¥48.97 Million | CN¥6.11 Million | CN¥71.92 Million | — |